Boniva (ibandronate sodium) Injection

MARCH 01, 2006

Roche (Nutley, NJ) and Glaxo-SmithKline (Research Triangle Park, NC) recently received FDA approval for Boniva Injection—the first intravenous (IV) medication indicated for the treatment of postmenopausal osteoporosis. The product is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis. Boniva Injection, administered as a 15-to 30-second IV injection, will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements. Furthermore, because the product will be administered once every 3 months by health care professionals, clinicians will have a greater awareness of patient compliance with therapy. Boniva Injection 3 mg/3 mL will be available in boxes containing one single- use, clear glass prefilled syringe, along with 1 needle and an alcohol swab. For more information, visit www.gsk.com or www.rocheusa.com.




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.